NL-OMON42887已完成不适用
Pharmacokinetic analysis of sinecathechins ointment 10% (Veregen) by means of Raman micro-spectroscopy in the skin of healthy volunteers - FARAO-study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 6
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Inclusion criteria
- •- Age between 18 and 40 years
- •- Written informed consent
排除标准
- •Exclusion criteria
- •- Extensive UV exposure in the last 14 days before study and/or expected during the study.
- •- Active skin disease and/or traumatic skin lesions including scars and tattoos on the forearms.
- •- Expected use of inflammation suppressing medicines (e.g. corticosteroids, NSAIDs) during the study.
- •- Use of systemic suppressing drugs (e.g. prednisone, methothrexate) prior to (4 weeks) the study and/or expected use during the study.
- •-Severe disorders within the last 6 months before study (e.g. cancer, acute cardiac or circularity disorders, HIV, infectious hepatitis)
- •-pregnancy or breastfeeding
- •- Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements.
研究者
相似试验
已完成
不适用
A pharmacokinetics study of green tea catechins after ingestion of green tea beverageot applicableJPRN-UMIN000042647Central Research Institute, ITO EN, Ltd.20
终止
2 期
Sexual Penetration Pain in Postmenopausal Women: A Topical Botanical Drug TreatmentSexual Pain DisordersPostmenopausal SymptomsVulvovaginal AtrophyVulvodyniaVestibulodyniaDyspareuniaArousal Disorders, SexualGenito-Pelvic Pain/Penetration DisorderFemale Sexual Arousal DisorderFemale Sexual DysfunctionNCT03682601GTO Pharmaceutical, LLC32
已完成
不适用
The effect of body weight on rivaroxaban disposition in healthy human volunteersRivaroxaban disposition in healthy human volunteers (obese vs non-obese population)ISRCTN12520248Qatar University36
进行中（未招募）
1 期
Pharmacokinetic study on echinocandins for patients with septic shock following secondary peritonitisEUCTR2016-002708-17-FRCHU de NIMES24
招募中
1 期
Evaluation of intravenous or subcutaneous administration of ublituximab in patients with multiple sclerosisCTIS2023-509555-13-00Tg Therapeutics Inc.60